| Name | Title | Contact Details |
|---|
Stardust Power Inc. is developing a strategically central, vertically-integrated lithium refinery capable of producing 50,000 tons per annum of battery-grade lithium. Committed to sustainability at each point in the process, the company enjoys a diversified supply of lithium from American brine sources. Stardust is comprised of leading industry, mining and finance experts, supported by a best-in-class advisory board and top technology partners. For more information, visit www.stardust-power.com.
Founded in 2018 and based near Green Bay, Wisconsin, closely held RC Mowers manufactures autonomous and remote-operated robotic mowers that solve the biggest challenges and improve opportunities for profitability and growth for landscaping contractors, public works departments, city, county, state and federal parks systems and roads departments, and more. All of our robotic mowers are designed and manufactured in the United States, have a 30-day buy-back guarantee and come with a 72-hour parts shipping guarantee. We are redefining the business of mowing.
MHI is a Japan-based multinational engineering company that owns and operates businesses in sectors such as energy, transportation and defense.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.